Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF Prostate Cancer Clinical Trials Consortium

BACKGROUND: Integrins mediate invasion and angiogenesis in prostate cancer bone metastases. We conducted a phase II study of Cilengitide, a selective antagonist of α(v)β(3) and α(v)β(5) integrins, in non-metastatic castration resistant prostate cancer with rising PSA. METHODS: Patients were observed...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Alva, Ajjai, Slovin, Susan, Daignault, Stephanie, Carducci, Michael, DiPaola, Robert, Pienta, Ken, Agus, David, Cooney, Kathleen, Chen, Alice, Smith, David C., Hussain, Maha
Médium: Artigo
Jazyk:Inglês
Vydáno: 2010
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3175265/
https://ncbi.nlm.nih.gov/pubmed/21049281
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9573-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky